<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485548</url>
  </required_header>
  <id_info>
    <org_study_id>2014NL-035</org_study_id>
    <nct_id>NCT02485548</nct_id>
  </id_info>
  <brief_title>Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer</brief_title>
  <official_title>A Multicenter Phase Ⅲ Trial of Cisplatin Plus Raltitrexed or 5-fluorouracil in Concurrence With Intensity-modulated Radiotherapy (IMRT) for the Treatment of Locoregionally Advanced Head and Neck Squamous Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuxi Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changzhou Cancer Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Jiangsu Province People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing BenQ Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter phase Ⅲ trial. The objective is to compare the efficacy and
      toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with IMRT for
      patients with locoregionally advanced head and neck squamous cell cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or
      5-fluorouracil in concurrence with IMRT for patients with locoregionally advanced head and
      neck squamous cell cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional and distant control rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing grade 3-5 adverse events(AEs)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Head and Neck Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Raltitrexed plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltitrexed plus cisplatin and IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-fluorouracil plus cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-fluorouracil plus cisplatin and IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>Patients will receive IMRT and concurrent raltitrexed and cisplatin</description>
    <arm_group_label>Raltitrexed plus cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>Patients will receive IMRT and concurrent 5-Fu and cisplatin</description>
    <arm_group_label>5-fluorouracil plus cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>All patients will receive concurrent cisplatin.</description>
    <arm_group_label>Raltitrexed plus cisplatin</arm_group_label>
    <arm_group_label>5-fluorouracil plus cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>All patients will receive IMRT</description>
    <arm_group_label>Raltitrexed plus cisplatin</arm_group_label>
    <arm_group_label>5-fluorouracil plus cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed untreated head and neck squamous cell cancer patients

          -  18-70 years

          -  Clinical stage: T3-4N0-3M0 or T1-4N1-3M0

          -  Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 10mg/dL

          -  Renal function: Cr ≤ 1.25×UNL

          -  Hepatic function: BIL ≤ 1.5×UNL, ALT/AST ≤ 2.5×UNL

          -  ECOG ≤ 1

          -  Woman and man of childbearing age must adopt contraception

          -  With written consent

        Exclusion Criteria:

          -  Malignant history

          -  Pregnant or lactating women

          -  With other severe diseases (blood, liver ,kidney or heart diseases)

          -  Subjects not suitable for chemo-radiotherapy

          -  Without written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia He, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Cancer Institute &amp; Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuesong Jiang, M.D.</last_name>
    <phone>86138517007</phone>
    <email>13851700790@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuesong Jiang, M.D.</last_name>
      <email>13851700790@126.com</email>
    </contact>
    <investigator>
      <last_name>Xuesong Jiang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Xia He</investigator_full_name>
    <investigator_title>Director of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

